Contraception development research center to advance a novel intravaginal ring as a non-hormonal multipurpose prevention technology
避孕开发研究中心将开发新型阴道环作为非激素多用途预防技术
基本信息
- 批准号:10324914
- 负责人:
- 金额:$ 200万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAdherenceAdvanced DevelopmentAdvisory CommitteesAnti-Bacterial AgentsAntiviral AgentsBacterial VaginosisBasic ScienceBehavioral SciencesBiomedical ResearchCharacteristicsChlamydiaClinical TrialsContraceptive AgentsContraceptive methodsCopperCross-Over StudiesCross-Sectional StudiesDataDevelopmentDevelopment PlansDimensionsDoseDrug Delivery SystemsDrug KineticsEnsureEvaluationFailureFellowshipFormulationFosteringFundingGoalsGonorrheaGrantHIVHIV InfectionsHIV-1HealthHormonesHumanHuman Herpesvirus 2In VitroIndustryInfertilityInvestigational DrugsInvestmentsLactic acidLeadMacaca mulattaMaternal MortalityMaternal and Child HealthMechanicsMedicalMenstruationMethodsNational Institute of Child Health and Human DevelopmentPathway interactionsPerformancePharmacologic ActionsPharmacologic SubstancePilot ProjectsPolymersPopulationPregnancyPremature BirthPreventionPrevention ResearchProdrugsProductionPropertyRegulatory AffairsReproductive HealthResearchResearch PersonnelResearch Project GrantsRiskSafetyScienceSexually Transmitted DiseasesSheepSideSocial SciencesTechnologyTemperatureTestingTimeLineToxic effectVaginaVaginal RingWomanWomen&aposs HealthWorkZincZinc Acetateantimicrobialcareerchronic pelvic paincollaborative environmentcombatcommunity engagementcontraceptive efficacydesignexperienceexperimental studyhealth goalsimprovedin vivoinnovationinterestnovelpreclinical studypreventproduct developmentprototypepublic health prioritiesresearch and developmentsafety studysensorsperm cellsuccesstechnology developmentunintended pregnancy
项目摘要
OVERALL – ABSTRACT
The overarching goal of the Population Council’s (PC) P50 proposal is to develop an innovative non-hormonal
multipurpose prevention technology (MPT) intravaginal ring (IVR) with the potential to improve the lives of
millions of women globally by combatting the overlapping burdens of unintended pregnancy and sexually
transmitted infections (STIs), including HIV. Emerging data indicate that women overwhelmingly prefer products
that prevent pregnancy and STIs/HIV over ones that prevent only pregnancy or only STI/HIVs. Our ‘CZL-IVR’ is
a user-controlled 30-day IVR containing three active pharmaceutical ingredients (APIs), copper (C), zinc acetate
(Z), and lactide (L) (a lactic acid prodrug) that together have non-hormonal contraceptive and anti-STI/HIV activity
including chlamydia (CT), gonorrhea (GC), HSV-2, and HIV-1. Lactide maintains optimal vaginal pH and provides
antibacterial, antiviral, and anti-bacterial vaginosis (BV) effects. We will advance development of our CZL-IVR
through implementation of three integrated research projects. In Project 1 we aim to formulate and manufacture
CZL-IVRs that achieve 30-day API delivery, manufacture and characterize in vitro mechanical performance of
IVRs with varying dimensions and polymers with the selection of four candidates with a range of mechanical
characteristics to evaluate in end-user research, and establish Good Manufacturing Practice (GMP) production
for non-medicated rings for research conducted in Project 3. In Project 2 we aim to define the optimal API
delivery doses of the three APIs alone and in combination, and to confirm the efficacy and safety of the prototype
CZL-IVR by conducting essential preclinical studies including in-vitro and in-vivo contraceptive efficacy and
antimicrobial efficacy and toxicity studies of APIs and of prototype human-sized and rhesus macaque-sized CZL-
IVRs. In Project 3 we will inform CZL-IVR development and the field more broadly through end-user research
employing novel mixed method approaches including a controlled setting cross-over study of the four selected
candidate non-medicated IVRs of varying mechanical characteristics, a 30-day continuous use study of a non-
medicated prototype IVR with an embedded temperature sensor, and a national cross-sectional survey with a
discrete choice experiment (DCE) and latent class analysis (LCA). The Administrative Core will support and
synergize our interdisciplinary collaborative research, provide scientific, administrative, and operational expertise
and oversight, and manage advisory committees to ensure adherence to timelines and success in achieving our
aims through rigorous science. Our P50 Center will be a hub fostering careers of early stage investigators and
inspiring MPT product development through fellowships and pilot project grants. Drawing from our world-class
Center for Biomedical Research and building on decades of successful contraceptive product development, the
PC’s P50 Center will capitalize on the rich, collaborative, and interdisciplinary environment and the vast
experience of the PC and our partners to advance development of an innovative MPT product.
总体--摘要
人口理事会(PC)P50提案的首要目标是开发一种创新的非激素
多用途预防技术(MPT)阴道内环(IVR)有可能改善患者的生活
通过应对意外怀孕和性行为的重叠负担,全球数百万妇女
传播感染(STI),包括艾滋病毒。最新数据显示,绝大多数女性更喜欢产品
与仅预防怀孕或仅预防性传播感染/艾滋病毒相比,预防怀孕和性传播感染/艾滋病毒。我们的‘CZL-IVR’
用户控制的30天IVR,包含三种活性药物成分(API)、铜(C)、醋酸锌
(Z)和丙交酯(L)(一种乳酸前体药物),它们一起具有非激素避孕和抗性传播感染/艾滋病毒活性
包括衣原体(CT)、淋病(GC)、HSV-2和HIV-1。丙交酯维持最佳阴道酸碱度,并提供
抗菌、抗病毒和抗细菌性阴道病(BV)的效果。我们将推进我们的CZL-IVR的发展
通过实施三个综合研究项目。在项目1中,我们的目标是制定和制造
实现30天原料药递送的CZL-IVRS、制造和表征体外力学性能
IVRS具有不同的尺寸和聚合物,可选择四个候选的机械范围
在最终用户研究中评估特性,并建立良好的制造规范(GMP)生产
用于项目3中进行的研究的非药物环。在项目2中,我们的目标是定义最佳原料药
三种原料药单独和联合给药的剂量,并确认原型的有效性和安全性
CZL-IVR通过进行基本的临床前研究,包括体外和体内避孕效果和
原料药、人体大小和猕猴大小的原型CZL的抗菌效果和毒性研究
IVRS。在项目3中,我们将通过终端用户研究向CZL-IVR的开发和更广泛的领域提供信息
采用新的混合方法,包括对选定的四个项目进行受控设置交叉研究
机械特性不同的候选非药物IVR,一项非药物连续使用30天的研究
带有嵌入式温度传感器的医用原型IVR,以及一项具有
离散选择实验(DCE)和潜在类分析(LCA)。行政核心将支持和
协同我们的跨学科协作研究,提供科学、管理和运营方面的专业知识
和监督,并管理咨询委员会,以确保遵守时间表并成功实现我们的
以严谨的科学为目标。我们的P50中心将成为促进早期调查人员和
通过奖学金和试点项目赠款激励MPT产品开发。取材于我们世界级的
生物医学研究中心在几十年成功的避孕产品开发的基础上,
PC的P50中心将利用丰富、协作和跨学科的环境以及
PC和我们的合作伙伴的经验,以推动创新的MPT产品的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisa Blake Haddad其他文献
Lisa Blake Haddad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lisa Blake Haddad', 18)}}的其他基金
Population Council Contraception Development Research Center Administrative Core
人口委员会避孕发展研究中心行政核心
- 批准号:
10324915 - 财政年份:2021
- 资助金额:
$ 200万 - 项目类别:
Contraception development research center to advance a novel intravaginal ring as a non-hormonal multipurpose prevention technology
避孕开发研究中心将开发新型阴道环作为非激素多用途预防技术
- 批准号:
10493305 - 财政年份:2021
- 资助金额:
$ 200万 - 项目类别:
Population Council Contraception Development Research Center Administrative Core
人口委员会避孕发展研究中心行政核心
- 批准号:
10493310 - 财政年份:2021
- 资助金额:
$ 200万 - 项目类别:
Population Council Contraception Development Research Center Administrative Core
人口委员会避孕发展研究中心行政核心
- 批准号:
10700066 - 财政年份:2021
- 资助金额:
$ 200万 - 项目类别:
Contraception development research center to advance a novel intravaginal ring as a non-hormonal multipurpose prevention technology
避孕开发研究中心将开发新型阴道环作为非激素多用途预防技术
- 批准号:
10700065 - 财政年份:2021
- 资助金额:
$ 200万 - 项目类别:
Emory Specialized Center of Research Excellence (SCORE) on Sex Differences
埃默里大学性别差异专业卓越研究中心 (SCORE)
- 批准号:
9790907 - 财政年份:2018
- 资助金额:
$ 200万 - 项目类别:
Immunologic changes associated with three progestin-based contraceptives: characterizing immune profiles over one year and identifying factors that may alter HIV risk
与三种孕激素避孕药相关的免疫学变化:描述一年内的免疫特征并确定可能改变艾滋病毒风险的因素
- 批准号:
10201695 - 财政年份:2018
- 资助金额:
$ 200万 - 项目类别:
Immunologic changes associated with three progestin-based contraceptives: characterizing immune profiles over one year and identifying factors that may alter HIV risk
与三种孕激素避孕药相关的免疫学变化:描述一年内的免疫特征并确定可能改变艾滋病毒风险的因素
- 批准号:
9754233 - 财政年份:2018
- 资助金额:
$ 200万 - 项目类别:
Immunologic changes associated with three progestin-based contraceptives: characterizing immune profiles over one year and identifying factors that may alter HIV risk
与三种孕激素避孕药相关的免疫学变化:描述一年内的免疫特征并确定可能改变艾滋病毒风险的因素
- 批准号:
10440378 - 财政年份:2018
- 资助金额:
$ 200万 - 项目类别:
Impact of progestin contraception on risk of HIV acquisition and transmission
孕激素避孕对艾滋病毒感染和传播风险的影响
- 批准号:
8732380 - 财政年份:2014
- 资助金额:
$ 200万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 200万 - 项目类别:
Fellowship Programs